FOXP3 and myeloid sarcoma: It is well established that FoxP3+ Tregs induce beneficial tolerance in MS patients by suppressing harmful myelin reactive T cells, [39] so the more variable and reduced Treg induction raises questions about the potential efficacy of generic especially given recent findings demonstrating Copaxone’s impact on Tregs [36] and linking Tregs to clinical response in MS patients [40].